Antral gastritis Medical Services in China

Antral gastritis is a localized form of chronic gastritis characterized by inflammation predominantly confined to the gastric antrum—the lower third of the stomach that connects to the pylorus and regulates gastric emptying. Unlike pangastritis or fundic-predominant gastritis, antral gastritis spares the acid-producing fundus and corpus in early stages, preserving basal acid secretion while often disrupting gastrin regulation and mucosal defense mechanisms. Pathogenesis centers on persistent mucosal injury from Helicobacter pylori infection—present in over 80% of cases—triggering chronic neutrophilic and lymphocytic infiltration, oxidative stress, and progressive glandular atrophy. Other contributors include long-term NSAID use, bile reflux (especially post-cholecystectomy or with impaired pyloric function), autoimmune mechanisms (less common than in corpus-predominant disease), and lifestyle factors such as smoking, heavy alcohol consumption, and chronic psychological stress. Epidemiologically, antral gastritis affects an estimated 30–50% of adults globally, with higher prevalence in low- and middle-income countries due to endemic H. pylori transmission. In China, seroprevalence exceeds 55% in adults over age 40, and antral-predominant patterns account for ~60% of biopsy-confirmed chronic gastritis cases. Risk factors include age >45 years, rural residence, crowded living conditions during childhood, untreated H. pylori infection, habitual NSAID or aspirin use, and comorbidities like type 2 diabetes and metabolic syndrome. While often asymptomatic in early stages, patients commonly report epigastric discomfort, early satiety, postprandial bloating, nausea, and intermittent dull pain—symptoms frequently mistaken for functional dyspepsia. Untreated, antral gastritis may progress to atrophic gastritis, intestinal metaplasia, and—over decades—elevate gastric cancer risk, particularly when combined with H. pylori virulence factors (CagA+/VacA+ strains) and host genetic susceptibility (e.g., IL-1β polymorphisms). Quality of life impact is substantial: patients report reduced work productivity, dietary restrictions (e.g., avoidance of spicy, acidic, or fatty foods), sleep disruption due to nocturnal discomfort, and heightened anxiety about malignancy—especially following endoscopic diagnosis with biopsy findings of metaplasia or dysplasia. Psychological burden is underrecognized; studies show 25–35% of patients meet criteria for health-related anxiety or mild depression linked to symptom chronicity and diagnostic uncertainty. Early diagnosis via high-definition upper endoscopy with targeted antral biopsies—and confirmation of H. pylori status via rapid urease test, histology, or stool antigen assay—is critical. Management focuses not only on symptom relief but also on mucosal healing, eradication of modifiable drivers, and surveillance stratification based on histopathological severity (e.g., OLGA/OLGIM staging).

Antral gastritis is a subtype of chronic gastritis characterized by predominant inflammatory changes localized to the gastric antrum—the distal portion of the stomach that connects to the pylorus. Unlike pangastritis or corpus-predominant gastritis, antral gastritis spares the fundus and body to a significant degree, though mild involvement may occur. Its pathogenesis involves a complex interplay of infectious, immunologic, environmental, and host-specific factors.

The most common cause is chronic Helicobacter pylori infection, implicated in over 80% of cases worldwide. H. pylori colonizes the antral mucosa preferentially due to its higher pH microenvironment and expresses virulence factors (e.g., CagA, VacA) that trigger neutrophil infiltration, lymphocyte activation, and epithelial cytokine release—culminating in chronic active inflammation. Eradication of H. pylori typically leads to histologic improvement, underscoring its central etiologic role.

Non-infectious triggers include prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, which inhibit cyclooxygenase-1 (COX-1), reducing prostaglandin synthesis critical for mucosal blood flow, mucus-bicarbonate secretion, and epithelial repair. This renders the antral mucosa more susceptible to acid-mediated injury and secondary inflammation. Other pharmacologic triggers include corticosteroids (especially with concomitant NSAID use), bisphosphonates, potassium chloride tablets, and selective serotonin reuptake inhibitors (SSRIs), which may induce direct mucosal irritation or alter motility and acid exposure patterns.

Autoimmune mechanisms are uncommon in isolated antral gastritis but may coexist in patients with atrophic gastritis extending from the antrum into the corpus; however, classic autoimmune gastritis (anti-parietal cell antibody–positive) predominantly affects the corpus and fundus and is rarely confined to the antrum. Thus, serologic markers such as intrinsic factor antibodies and serum gastrin levels are typically normal in pure antral gastritis, distinguishing it from autoimmune disease.

Genetic susceptibility plays a modulatory role. Polymorphisms in proinflammatory cytokine genes—including IL-1β (IL1B-511T and -31C alleles), IL-10 (IL10-592A), and TNF-α (TNFA-308A)—are associated with increased risk of H. pylori–induced antral inflammation and progression to atrophy or intestinal metaplasia. These variants amplify mucosal immune responses, impair bacterial clearance, and promote sustained tissue injury. Additionally, polymorphisms in TLR4 (Toll-like receptor 4) and CD14 influence innate immune recognition of H. pylori lipopolysaccharide, affecting colonization density and inflammatory severity.

Environmental and lifestyle risk factors are well-established. Smoking increases gastric acid secretion, reduces mucosal blood flow, impairs bicarbonate production, and delays gastric emptying—thereby prolonging antral exposure to noxious agents. Heavy alcohol consumption induces direct cytotoxic effects on surface epithelial cells, disrupts tight junctions, and stimulates gastric acid hypersecretion, particularly exacerbating antral vulnerability due to its relatively lower mucosal defense capacity compared to the acid-secreting corpus. Dietary factors—including high intake of salted, smoked, or nitrate-rich foods—promote oxidative stress and N-nitroso compound formation, contributing to epithelial DNA damage and chronic inflammation. Conversely, diets rich in antioxidants (vitamins C and E, selenium), cruciferous vegetables, and probiotic-containing fermented foods appear protective.

Socioeconomic determinants also contribute: overcrowded living conditions, poor sanitation, and limited access to clean water increase early-life H. pylori acquisition and persistent colonization. Occupational exposures—such as chronic stress in high-demand professions—may dysregulate autonomic and neuroendocrine pathways, altering gastric motility, acid output, and mucosal immunity via vagal and hypothalamic-pituitary-adrenal axis modulation. Psychological stress does not directly cause antral gastritis but can potentiate symptom perception, delay healing, and worsen mucosal barrier dysfunction through mast cell activation and substance P release.

Less common causes include bile reflux (often post-cholecystectomy or after gastric surgery), where duodenogastric reflux introduces bile acids and pancreatic enzymes that disrupt the antral mucosal barrier; eosinophilic gastritis (with peripheral eosinophilia and tissue eosinophil infiltration); and granulomatous gastritis (e.g., sarcoidosis, Crohn’s disease). Rarely, radiation-induced gastritis or drug-induced vasculitis may manifest predominantly in the antrum.

In summary, antral gastritis arises primarily from H. pylori infection and NSAID exposure, amplified by genetic predisposition, smoking, alcohol, dietary carcinogens, and socioeconomic adversity. Recognition of these multifactorial contributors is essential for targeted diagnosis, risk stratification, and personalized management in gastroenterology practice.

Antral gastritis is a chronic inflammatory condition predominantly affecting the gastric antrum—the distal portion of the stomach situated between the corpus and the pylorus. As a subtype of chronic gastritis, it is most commonly associated with Helicobacter pylori infection, but may also arise from autoimmune mechanisms, long-term NSAID use, bile reflux, or environmental factors such as smoking and excessive alcohol consumption. Its clinical presentation is highly variable; many patients remain asymptomatic, particularly in early or mild stages, while others experience nonspecific upper gastrointestinal symptoms that often overlap with functional dyspepsia or other gastroduodenal disorders.

Early symptoms are frequently subtle and nonspecific, reflecting low-grade mucosal irritation rather than overt structural damage. Patients may report intermittent epigastric discomfort described as a dull, burning, or gnawing sensation—typically occurring postprandially or on an empty stomach. Mild anorexia, early satiety after small meals, and occasional bloating without significant distension are common initial complaints. Some individuals notice a vague sense of fullness or pressure in the upper abdomen, especially after fatty or spicy foods. Nausea may occur sporadically but is rarely severe or persistent at this stage. Importantly, early antral gastritis seldom presents with alarm features such as hematemesis, melena, weight loss, or dysphagia—these warrant urgent evaluation for malignancy or complications.

Typical symptoms emerge as inflammation progresses and mucosal integrity deteriorates. Persistent or recurrent epigastric pain becomes more frequent and may follow a pattern—worsening 1–3 hours after meals or during fasting, partially relieved by antacids or food ingestion. Dyspepsia dominates the clinical picture: defined by at least one of the following—postprandial fullness, early satiety, epigastric pain or burning, or epigastric discomfort—occurring at least once per week over the preceding three months. Belching (eructation) and sour or bitter regurgitation may be reported, particularly if concurrent duodenogastric reflux is present. In H. pylori–associated cases, patients may describe a metallic taste or halitosis. Notably, symptom severity does not reliably correlate with endoscopic or histologic findings; some individuals with extensive antral atrophy exhibit minimal symptoms, whereas others with mild inflammation report debilitating discomfort.

Accompanying symptoms reflect systemic or secondary effects of chronic gastric inflammation. Mild iron-deficiency anemia may develop due to chronic occult blood loss or impaired iron absorption secondary to hypochlorhydria and reduced gastric acid–mediated ferric iron reduction. Vitamin B12 deficiency is less common in isolated antral gastritis (as parietal cells reside predominantly in the corpus), but can occur in advanced cases with concomitant corpus involvement or autoimmune extension. Patients may report fatigue, lightheadedness, or pallor attributable to anemia. Functional gastrointestinal disturbances—including constipation or alternating bowel habits—may coexist, though causality remains unclear. Psychological comorbidities such as anxiety and depression are frequently observed, likely reflecting bidirectional brain-gut axis dysregulation rather than direct pathophysiology. Some patients report exacerbation of symptoms under psychological stress, suggesting neuroimmune modulation of gastric sensitivity and motility.

Complications of untreated or refractory antral gastritis include gastric atrophy, intestinal metaplasia, and dysplasia—constituting steps along the Correa cascade toward gastric adenocarcinoma. While antral-predominant disease carries lower malignant potential than pangastritis or autoimmune gastritis, longitudinal studies confirm increased risk of gastric cancer, particularly when combined with H. pylori virulence factors (e.g., CagA-positive strains) or environmental cofactors (e.g., high-salt diet, smoking). Peptic ulcer disease may develop due to disrupted mucosal defense mechanisms and localized acid hypersecretion—paradoxically, antral inflammation can impair somatostatin release from D-cells, leading to disinhibited gastrin secretion from G-cells and subsequent acid overproduction. Gastric outlet obstruction is rare but possible in cases complicated by fibrotic scarring or severe edema. Additionally, chronic antral inflammation contributes to delayed gastric emptying (gastroparesis-like symptoms) via disruption of interstitial cells of Cajal and neuromuscular signaling.

Diagnosis relies on a multimodal approach. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard, enabling direct visualization of antral mucosa—findings may include erythema, edema, erosions, friability, mucosal granularity, or loss of vascular pattern. Biopsy specimens should be obtained from the antrum (greater and lesser curvature) and corpus for histopathological assessment per the Updated Sydney System, evaluating inflammation, activity (neutrophils), atrophy, metaplasia, and H. pylori status. Non-invasive testing includes urea breath test (UBT), stool antigen test (SAT), and serology—though serology cannot distinguish current from past infection and lacks utility post-eradication. Serum pepsinogen I/II ratio and gastrin-17 levels may support assessment of atrophic changes but require validation in local populations. Imaging modalities such as contrast-enhanced CT or MRI lack sensitivity for mucosal inflammation and are not indicated for routine diagnosis.

Differential diagnosis is essential to avoid misclassification. Functional dyspepsia shares identical symptom profiles but lacks objective evidence of organic disease on endoscopy and histology. Peptic ulcer disease typically presents with more localized, predictable pain and may demonstrate endoscopic ulcers. Gastroesophageal reflux disease (GERD) features retrosternal burning, regurgitation, and response to proton pump inhibitors—but lacks true antral inflammation. Autoimmune gastritis predominantly involves the gastric corpus, presenting with achlorhydria, pernicious anemia, and elevated anti-parietal cell antibodies—whereas antral gastritis preserves acid output initially. Gastric lymphoma (MALT lymphoma) may mimic chronic gastritis endoscopically but demonstrates lymphoid follicles, architectural distortion, and clonal B-cell expansion on biopsy. Other considerations include eosinophilic gastritis (eosinophil-predominant infiltration), Crohn’s disease (transmural inflammation, skip lesions, granulomas), and Zollinger-Ellison syndrome (hypergastrinemia, multiple ulcers, pancreatic tumors). Careful integration of clinical history, endoscopic appearance, histopathology, and targeted laboratory testing ensures accurate distinction and guides appropriate management.

Antral gastritis refers to chronic inflammation localized predominantly to the gastric antrum—the distal portion of the stomach that connects to the pylorus and duodenum. It is commonly associated with Helicobacter pylori (H. pylori) infection, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), bile reflux, autoimmune phenomena, or lifestyle-related factors such as excessive alcohol intake, smoking, and chronic stress. Diagnosis typically relies on upper gastrointestinal endoscopy with targeted biopsies, histopathological assessment (including evaluation for intestinal metaplasia, atrophy, or dysplasia), and confirmatory testing for H. pylori (e.g., rapid urease test, stool antigen assay, or PCR-based detection). Given its multifactorial etiology and variable clinical presentation—from asymptomatic mucosal changes to epigastric discomfort, early satiety, nausea, or iron-deficiency anemia—management must be individualized, evidence-based, and stratified by severity, etiology, and risk for complications.

Conservative treatment forms the cornerstone of management for most patients with mild-to-moderate antral gastritis. This includes strict dietary modification: avoidance of irritants such as spicy foods, caffeine, carbonated beverages, and highly acidic or fried items; adoption of small, frequent meals to reduce gastric distension and acid exposure; and elimination of alcohol and tobacco, both of which impair mucosal defense mechanisms and delay healing. Stress reduction techniques—including cognitive behavioral therapy, mindfulness-based stress reduction, and regular physical activity—are recommended adjuncts, given the well-documented bidirectional relationship between psychological stress and gastric mucosal integrity. Patients are also advised to discontinue NSAIDs when clinically feasible; if analgesia remains necessary, acetaminophen or COX-2 selective inhibitors (with concurrent proton pump inhibitor [PPI] coverage) may be considered under gastroenterologist supervision.

Pharmacologic therapy is tailored to the underlying cause. For H. pylori–positive cases, first-line eradication regimens follow international consensus guidelines (e.g., Toronto Consensus, ACG Clinical Guideline) and local antimicrobial resistance patterns. In China, where clarithromycin resistance exceeds 25%, bismuth-containing quadruple therapy (PPI + bismuth subsalicylate + tetracycline + metronidazole) for 10–14 days is preferred over standard triple therapy. High-dose dual therapy (esomeprazole 40 mg three times daily + amoxicillin 1 g three times daily) is increasingly utilized in regions with documented high-amoxicillin susceptibility. All regimens require post-treatment confirmation of eradication via urea breath test or stool antigen test at least four weeks after therapy completion. For H. pylori–negative, NSAID-induced, or reflux-associated antral gastritis, acid suppression remains central: PPIs (e.g., omeprazole 20 mg, esomeprazole 40 mg, or rabeprazole 20 mg once daily) are administered for 4–8 weeks, followed by step-down or on-demand dosing based on symptom control and endoscopic reassessment. In cases of bile reflux gastritis, ursodeoxycholic acid (13–15 mg/kg/day) or bile acid sequestrants (e.g., cholestyramine) may be trialed, though evidence remains limited. Mucosal protectants—including rebamipide (100 mg three times daily) and teprenone (50 mg three times daily)—are widely used in Asia to enhance prostaglandin synthesis, stimulate mucus/bicarbonate secretion, and promote epithelial restitution; these agents are particularly beneficial in chronic atrophic antral gastritis with impaired mucosal repair capacity.

Surgical intervention is exceedingly rare in isolated antral gastritis and is reserved only for refractory, complication-driven scenarios. Indications include severe, medically unresponsive bleeding from erosive antral lesions (e.g., Dieulafoy lesion confined to the antrum), gastric outlet obstruction secondary to fibrotic antral stenosis (often in longstanding autoimmune or granulomatous gastritis), or suspicion of malignancy in the context of high-grade dysplasia or early gastric adenocarcinoma arising within chronically inflamed antral mucosa. Laparoscopic antrectomy or partial gastrectomy may be performed in select centers, but endoscopic resection (e.g., endoscopic submucosal dissection) is preferred for localized neoplastic lesions. Surgery is never indicated for routine inflammatory changes and carries risks including dumping syndrome, nutritional deficiencies (especially vitamin B12, iron, calcium), and postgastrectomy syndromes—thus requiring rigorous preoperative risk-benefit analysis and multidisciplinary input.

Treatment in China offers several distinct advantages. First, China’s national endoscopy infrastructure supports widespread access to high-definition magnifying endoscopy with narrow-band imaging (NBI) and linked-color imaging (LCI), enabling real-time differentiation of gastritis subtypes and early neoplastic changes. Second, integrated H. pylori resistance surveillance networks (e.g., the China Antimicrobial Resistance Surveillance Network) inform regional guideline adaptations, improving eradication success rates (>90% in tertiary centers using culture-guided or molecular resistance testing). Third, traditional Chinese medicine (TCM) is systematically incorporated into integrative protocols: formulas such as Weikangning decoction or Huangqin Tang—standardized for quality and pharmacokinetics—demonstrate anti-inflammatory, antioxidant, and H. pylori–inhibitory effects in randomized controlled trials, and are approved by the National Medical Products Administration (NMPA) as adjunctive therapy. Fourth, China’s tiered healthcare system facilitates seamless referral from community clinics to specialized digestive disease hospitals, ensuring timely access to advanced diagnostics (e.g., serum pepsinogen I/II ratio, gastrin-17 assays for atrophic gastritis staging) and longitudinal monitoring.

Recovery advice emphasizes sustained mucosal healing and prevention of recurrence. Patients should undergo repeat endoscopy at 6–12 months if initial biopsy revealed atrophy, intestinal metaplasia, or persistent H. pylori infection despite therapy. Lifestyle adherence must continue indefinitely: strict avoidance of NSAIDs without gastroprotection, moderation of alcohol, and maintenance of a low-inflammatory diet rich in antioxidants (e.g., cruciferous vegetables, berries, green tea). Vitamin supplementation—particularly vitamin B12 (intramuscular or high-dose oral), iron, and folate—is recommended for patients with confirmed atrophic gastritis and hypochlorhydria. Regular follow-up with a gastroenterologist every 6–12 months is advised for those with premalignant changes, incorporating serologic biomarkers and risk-stratified surveillance intervals per the Updated Sydney System and Asian Pacific Guidelines. Finally, patient education regarding symptom recognition (e.g., new-onset anemia, weight loss, persistent vomiting) and prompt reporting is critical to mitigate progression to gastric cancer—a known sequela of untreated chronic antral gastritis, especially in high-risk populations.